SOURCE: ArtVentive Medical Group, Inc.

ArtVentive Medical Group, Inc.

October 14, 2014 08:15 ET

ArtVentive Medical Group, Inc. Announces Expanded Commercial Use and Post-Market Study of EOS™ Endoluminal Occlusion System

CARLSBAD, CA--(Marketwired - Oct 14, 2014) - ArtVentive Medical Group, Inc. (OTCBB: AVTD) announced today additional excellent clinical results in the ongoing ArtVentive EOS™ Endoluminal Occlusion System, or ArtVentive EOS™, OCCLUDE I post-market surveillance study.

The Company announced that commercial cases were performed at The University Hospital, Leuven, Belgium, where Dr. Geert Maleux successfully treated two patients with the ArtVentive EOS™ device. Dr. Maleux, Professor in the Department of Radiology stated, "The ArtVentive EOS™ device enhances our ability to treat challenging embolization cases. It offers immediate and total occlusion, and the operator can have confidence that the target vessel is occluded. In addition to this desirable clinical outcome, the ArtVentive EOS™ technology allows for shorter procedure times and reduced radiation exposure for both the physician and patient."

"We are excited about the success of the ArtVentive EOS™ device and the momentum in usage as we expand our distribution of ArtVentive EOS™ across the European markets," said Jim Graham, ArtVentive's Chief Executive Officer. "Our entire team is energized by the excellent clinical results and we look to increasing our market penetration as awareness of the ArtVentive EOS™ platform grows. As a result of the continued market support, as evidenced at the recent Cardiovascular and Interventional Radiology Society of Europe (CIRSE) conference in Glasgow, Scotland, we will begin distributing ArtVentive EOS™ in several additional European countries during the fourth quarter."

The Company also reported that two male patients were treated for varicoceles with the ArtVentive EOS™ device at The Regional Hospital of Lugano, Switzerland. Dr. Josua Van den Berg, Head of Service of Interventional Radiology, was the attending physician for the procedures.

Dr. Leon Rudakov, President of ArtVentive, added, "We expect to commence additional commercial and study cases in the Netherlands and Germany in the fourth quarter, which will focus on the performance of the ArtVentive EOS™ platform in venous, as well as arterial settings during the OCCLUDE II studies. We will continue to share this important clinical data from the podium through publications and in training settings."

About ArtVentive Medical Group, Inc. 
ArtVentive Medical Group, Inc., with corporate headquarters in Carlsbad, California, is an innovative, multi-faceted medical device company focused on developing, manufacturing and marketing globally a family of devices featuring the ArtVentive EOS™.

The ArtVentive EOS™ is catheter-based, self-expandable and facilitates permanent or temporary occlusion of peripheral body lumens, cavities occurring within the body's vascular system and organ network. The ArtVentive EOS™ is designed to serve as a safe and reliable alternative to major surgery in certain cases. This technological innovation brings current interventional, image-guided techniques to a new level of sophistication, with the potential to resolve significant health issues. 

The ArtVentive EOS™ serves as a proprietary technology platform for several major clinical areas, including peripheral and neurological vascular disorders, women's health (minimally invasive contraceptive and birth control), interventional cardiology, pulmonary and interventional oncology procedures.

More information about ArtVentive can be found at

Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to the Company's current expectations, projections and beliefs concerning matters that are not historical facts. Forward-looking statements are not guarantees of future performance. Forward-looking statements involve uncertainties, risks, assumptions and contingencies, many of which are outside the Company's control, and, thus, actual results could differ materially from those described in or implied by any forward-looking statement. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. The Company assumes no obligation to update any forward-looking statement made in this news release that becomes untrue because of subsequent events, new information or otherwise, except to the extent it is required to do so in connection with the Company's ongoing requirements under federal securities laws. For a further discussion of factors that could cause the Company's future results to differ materially from any forward-looking statements, see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. 

Contact Information